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Abstract
The influence of 3D microenvironments on apoptosis susceptibility remains poorly understood. Here, we studied the
susceptibility of cancer cell spheroids, grown to the size of micrometastases, to tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). Interestingly, pronounced, spatially coordinated response heterogeneities manifest within
spheroidal microenvironments: In spheroids grown from genetically identical cells, TRAIL-resistant subpopulations enclose,
and protect TRAIL-hypersensitive cells, thereby increasing overall treatment resistance. TRAIL-resistant layers form at the
interface of proliferating and quiescent cells and lack both TRAILR1 and TRAILR2 protein expression. In contrast, oxygen,
and nutrient deprivation promote high amounts of TRAILR2 expression in TRAIL-hypersensitive cells in inner spheroid
layers. COX-II inhibitor celecoxib further enhanced TRAILR2 expression in spheroids, likely resulting from increased ER
stress, and thereby re-sensitized TRAIL-resistant cell layers to treatment. Our analyses explain how TRAIL response
heterogeneities manifest within well-defined multicellular environments, and how spatial barriers of TRAIL resistance can
be minimized and eliminated.
Introduction
The cytokine tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a member of the TNF super-
family and can trigger caspase-8-dependent apoptosis in
transformed cells by binding and activating two receptors,
TRAIL receptor 1 (TRAILR1) and TRAIL receptor 2
(TRAILR2) [1, 2]. Various TRAIL-based therapeutics have
been developed in the recent years, including aggregated
TRAIL variants, TRAILR-binding agonistic antibodies, and
multivalent antibody-TRAIL fusion proteins that show
increased stability and activity in comparison to soluble
recombinant human TRAIL (dulanermin) [1, 3]. Following
binding, TRAILRs oligomerize into the death inducing sig-
naling complex (DISC), which also comprises of Fas-
associated protein with death domain (FADD). Procaspase-8
binds to FADD and forms filaments in which procaspase-8 is
auto-proteolytically cleaved and activated [4–7]. By compet-
ing with procaspase-8 for binding to the elongating filaments,
cellular FLICE-like inhibitory protein (cFlip), a procaspase-8
homolog lacking protease activity, can inhibit the full acti-
vation and processing of procaspase-8 [8]. High amounts of
active caspase-8 and/or low concentrations of effector caspase
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inhibitor XIAP allow direct activation of effector caspase-3
and apoptosis execution [9, 10]. However, in most cells
caspase-8 must cleave the BH3-only protein Bid to truncated
Bid (tBid), which translocates to the outer mitochondrial
membrane to induce the formation of Bak and Bax pores,
which induces apoptosome-dependent caspase-3 activation
and apoptosis execution. The threshold for whether tBid can
induce Bax/Bak pores or not is set by antiapoptotic members
of the Bcl-2 protein family [11].
First generation TRAILR agonists were described as
potent apoptosis inducers in cellular models of various can-
cers, however, therapeutic candidates so far performed rather
disappointingly. In phase I and phase II clinical trials, only
few patients responded to treatment with dulanermin or
TRAILR-specific agonistic antibodies, such as Mapatumu-
mab (anti-TRAILR1) and Conatumumab (anti-TRAILR2)
[3, 12]. Besides insufficient receptor oligomerisation, an
aspect that has been addressed by the development of mul-
tivalent antibody-TRAIL fusion proteins of superior potency
[13, 14], in vivo half times of dulanermin, lying in the range
of hours, also considerably limited clinical efficacy [12]. For
TRAIL-based treatments to be effective, it is therefore crucial
that cancer cell killing can be achieved rapidly and that
TRAIL-based therapeutics encounter TRAIL responsive cells
also in deeper layers of solid tumors.
Compared with conventional adherent cell cultures, cancer
cell spheroids, grown to sizes of micrometastases, and
resembling cellular interactions and architectures found in
avascular tumor tissues, offer more advanced but nevertheless
well controllable experimental models suited to assess drug
treatment efficacies and to study the modulation of cellular
responsiveness to treatment as a consequence of the spheroid
microenvironment [15]. Here, we therefore studied the
TRAIL responsiveness of spheroids and discovered that the
spheroid microenvironment gives rise to layers of TRAIL-
resistant cells. These TRAIL-resistant cells prevent apoptosis
induction in TRAIL-hypersensitive cells that develop deeper
within the spheroids, and thereby increase overall TRAIL
resistance. This can be counteracted by intensifying micro-
environmental stress that drives TRAILR2 expression.
Materials and methods
Reagents and antibodies
QVD (Q-VD-OPH) and celecoxib were purchased from
Selleckchem (Houston, TX, USA). IZI1551 (TRAIL) was
produced as described before [14]. Annexin V-EGFP was
produced in-house. DAPI (4′,6-diamidin-2-phenylindol) was
obtained from Thermo Fisher Scientific (Waltham, MA,
USA). DMSO was purchased from Carl Roth (Karlsruhe,
Germany). The following antibodies were used for flow
cytometry: mouse monoclonal TRAILR1 (MAB347, R&D
Systems, Wiesbaden-Nordenstadt, Germany), mouse mono-
clonal TRAILR2 (MAB6311, R&D Systems, Wiesbaden-
Nordenstadt, Germany), mouse monoclonal FADD
(ab119059, Abcam, Cambridge, UK), mouse monoclonal Flip
(7F10, Enzo Life Sciences, Lorrach, Germany), rabbit
monoclonal procaspase-8 (ab32125, Abcam, Cambridge,
UK), rabbit monoclonal Ki67 (D3B5, Cell Signaling, Dan-
vers, MA, USA), purified mouse IgG1 κ istotype control and
purified mouse IgG2b κ istotype control (BD Biosciences,
Heidelberg, Germany), rabbit isotype control (DA1E, Cell
Signaling, Danvers, MA, USA), and goat antirabbit Alexa
Flour 647 (IgG (H+L) highly cross-adsorbed, A-21245),
goat antimouse Alexa 488 (IgG (H+L) highly cross-adsor-
bed, A-11029), goat antirabbit Alexa 488 (IgG (H+ L) highly
cross-adsorbed, A-11008) from Thermo Fisher Scientific
(Waltham, MA, USA). The following antibodies were used
for western blotting: rabbit monoclonal LC3B (D11, Cell
Signaling, Danvers, MA, USA), mouse monoclonal α-tubulin
(DM1A), rabbit monoclonal COX IV (3E11), mouse mono-
clonal GAPDH (D4C6R), mouse monoclonal Hif-1α
(D5F3M), rabbit monoclonal TRAILR1 (D9S1R), rabbit
monoclonal TRAILR2 (D4E9), rabbit polyclonal FADD,
rabbit monoclonal Flip (D16A8), rabbit monoclonal cFlip-L/-
S (D5J1E), rabbit monoclonal Caspase-8 (D35G2), mouse
monoclonal Caspase-8 (1C12), rabbit monoclonal XIAP
(D2Z8W), rabbit polyclonal cleaved Caspase-3 and rabbit
monoclonal Caspase-3 (8G10) from Cell Signaling (Danvers,
MA, USA), mouse monoclonal CHOP (GADD 153 (B-3): sc-
7351, Santa Cruz, Santa Cruz, CA, USA), antimouse IgG
HRP-linked antibody and antirabbit IgG HRP-linked antibody
from Cell Signaling (Danvers, MA, USA), IRDye® 800CW
goat antimouse IgG secondary antibody and IRDye® 680RD
goat antirabbit IgG secondary antibody from LI-COR Bios-
ciences (Lincoln, NE, USA). The following antibodies were
used for immunohistochemistry: mouse monoclonal Hif-1α
(BD Biosciences, Heidelberg, Germany), rabbit monoclonal
thymidine kinase 1 (EPR3191, Abcam, Cambridge, UK), goat
polyclonal TRAILR1 (sc-6823, Santa Cruz, Santa Cruz, CA,
USA), mouse monoclonal TRAILR2 (TR2.21, AdipoGen
Life Science, Liestal, Switzerland), bridging antibody rabbit
antigoat (Gentaur, Aachen, Germany). For immuno-
fluorescence staining of Ki67, mouse monoclonal Ki67 (8D5)
from Cell Signaling (Danvers, MA, USA) and goat antimouse
Alexa 647 (IgG (H+ L) highly cross-adsorbed, A-21236,
Thermo Fisher Scientific, Waltham, MA, USA) was used.
Cell culture
NCI-H460 cells were purchased from ATCC (Manassas,
VA, USA), HCT116 cells were obtained from the Banca
Biologica e Cell Factory of the IRCCS Azienda Ospe-
daliera Universitaria San Martino in Genoa (ICLC
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HTL95025). Simian virus 40 large T-immortalized mur-
ine embryonic fibroblasts from TNFR1/TNFR2 double
knockout mice that stably express either human
TRAILR1 or human TRAILR2 (MEF-hT1; MEF-hT2)
were kindly provided by Dr Simon Neumann (University
of Stuttgart, Germany). TRAILR1 deficient HCT116 cells
(HCT116 T1 k/o), TRAILR1 deficient NCI-H460 cells
(NCI-H460 T1 k/o), TRAILR2 deficient HCT116 cells
(HCT116 T2 k/o) and TRAILR2 deficient NCI-H460
cells (NCI-H460 T2 k/o) were generated by CRISPR/
Cas9-based gene targeting. HCT116 cells were trans-
fected with the guide RNA containing vector via lipo-
fectamine while NCI-H460 cells underwent lentiviral
transduction. Oligos coding for the guide RNA were
ordered from biomers.net. Guide RNA against TRAILR1
in HCT116: 5′-CACCgCGTGGTTCAATCCTCCCCG-3′
(forward), 5′-AAACCGGGGAGGATTGAACCACGC-3′
(revers). Guide RNA against TRAILR2 in HCT116: 5′-
CACCGCAGAACGCCCCGGCCGCTT-3′ (forward), 5′-
AAACAAGCGGCCGGGGCGTTCTGC-3′ (reverse).
Both oligos were annealed and ligated into pSpCas9(BB)-
2A-GFP ((PX458), (#48138), Addgene, Watertown, MA,
USA). Two days after cell transfection, GFP positive
clones were sorted (BD5 FACSAriaTM III, BD Bios-
ciences, Heidelberg, Germany) and analyzed for suc-
cessful TRAILR knockout by flow cytometry and western
blotting after 2–3 weeks of cultivation. Guide RNA
against TRAILR1 in NCI-H460: 5′-CACCGAGTA
CATCTAGGTGCGTTCC-3′ (forward), 5′-AAACGGAA
CGCACCTAGATGTACTC-3′ (revers). Guide RNA
against TRAILR2 in NCI-H460: 5′-CACCGATAG
TCCTGTCCATATTTGC-3′ (forward), 5′-AAACGCA
AATATGGACAGGACTATC-3′ (revers). Both oligos
were annealed and ligated into lentiCRISPRv2 (#52961,
Addgene, Watertown, MA, USA). To produce the lenti-
viral particles for the transduction of NCI-H460 cells,
HEK293T cells were transfected with the vector con-
taining the guide RNA together with a vector for viral
packaging (psPAX2, #12260, Addgene, Watertown, MA,
USA) and for the viral envelope (pCMV-VSV-G, #8454,
Addgene, Watertown, MA, USA) using lipofectamine.
After selection with puromycin, the pool of cells was
sorted for the absence of TRAILR expression using pri-
mary and Alexa 488 labeled secondary antibodies (mouse
monoclonal TRAILR1 (MAB347, R&D Systems, Wies-
baden-Nordenstadt, Germany), goat antimouse Alexa 488
(IgG (H+ L) highly cross-adsorbed, A-11029, Thermo
Fisher Scientific, Waltham, MA, USA)). Obtained single
clones were analysed for successful TRAILR knockout
by flow cytometry and western blotting after 2–3 weeks
of cultivation.
All cell lines were grown in Roswell Park Memorial
Institute medium (RPMI, Thermo Fisher Scientific, Gibco,
Waltham, MA, USA) with 10% FCS (fetal calf serum,
PAN-Biotech, Aidenbach, Germany) except for NCI-H460
cells that were cultured with 5% FCS. For generation of
spheroids, cells were seeded into Terasaki multiwell plates
(100 cells/well, Greiner Bio-One, Frickenhausen, Germany)
and placed in humid chambers in the incubator. After 3 days
of cultivation, spheroids were transferred to agarose-coated
96-well plates (F-bottom, Greiner Bio-One, Frickenhausen,
Germany). Medium was changed every second to third day.
To induce hypoxia, 2D-cultured cells were placed in a
hypoxia chamber (O2 Control InVitro Glove Box, Coy
Laboratory Products, Grass Lake, MI, USA; 1% oxygen,
5% CO2, 37 °C, and 96% relative humidity). At the end of
experiments, cells were harvested inside of the hypoxia
chamber and immediately put on ice. All articles and media
were gas equilibrated within the hypoxic chamber at least
24 h prior to usage. For experiments with nutrient depri-
vation, 2D-cultivated cells were grown in RPMI containing
10% FCS and either 2, 1, 0.5, or 0.25 mg/ml glucose (Carl
Roth, Karlsruhe, Germany) or RPMI medium without FCS
and with 2 mg/ml glucose. All cell lines were regularly
tested for mycoplasma infection and their authenticity was
verified by STR profiling.
Cell death measurements
Cells were harvested or spheroids were dissociated with
trypsin/EDTA (Thermo Fisher Scientific, Gibco, Waltham,
MA, USA), stained with Annexin V-EGFP in Annexin V-
EGFP binding buffer (BD Biosciences, Heidelberg, Ger-
many) for 10 min at room temperature, and then analyzed
by flow cytometry (MACSQuant Analyzer 10, Miltenyi
Biotec, Bergisch Gladbach, Germany).
qPCR
RNA was extracted using the RNeasy Plus Mini Kit
(QIAGEN, Hilden Germany), following the manufacturer’s
instruction. RNA concentrations were measured on a
NanoDrop Spectrophotometer ND-1000, (Thermo Fisher
Scientific). For the generation of cDNA, RNA extracts were
diluted with RNase-free water (1:10) and RNA (100 ng)
was mixed with 2 μl wipe out buffer (QuantiTect Reverse
Transcriptase Kit, QIAGEN, Hilden, Germany). After
incubation at 42 °C for 2 min, reverse transcriptase (RTase),
RTase buffer, and RTase primers were added and samples
were incubated, first for 15 min at 42 °C and then 3 min at
95 °C, following the manufacturer’s instructions (Quanti-
Tect Reverse Transcriptase Kit, QIAGEN). cDNA con-
centrations were determined prior to qPCR. Primers were
designed with Primer-BLAST from NCBI and ordered from
biomers net (Ulm, Germany). Primers were mixed with
cDNA (100 ng) and DyNAmo ColorFlash SYBR Green
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qPCR Mix (2×) following the manufacturer’s instructions
(DyNAmo ColorFlash SYBR Green qPCR Kit, Biozym,
Hessisch Oldendorf, Germany) and reactions were mea-
sured on a qPCR Cfx96 device (Biorad, Hercules, CA,
USA). Fold change expression of mRNA was calculated by
the ΔΔCt method using the CFX Manager Software
(Biorad, Hercules, CA, USA). The following qPCR primers
were used: GAPDH: 5′-CCCCTTCATTGACCTCAACT
A-3′ (forward primer) 5′-CGCTCCTGGAAGATGGTG
AT-3′ (reverse primer); TRAILR1: 5′-GGTTGTTCCGTT
GCTGTTGG-3′ (forward primer), 5′-CCAGAAACACAC
CCTGTCCAT-3′ (reverse primer); TRAILR2-L: 5′-CCC
TGTTCTCTCTCAGGCATC-3′ (forward primer), 5′-CA
GGTCGTTGTGAGCTTCTGT-3′ (reverse primer);
TRAILR2-S: 5′-GTCCACAAAGAATCAGGCATC-3′
(forward primer), 5′- CCAGGTCGTTGTGAGCTTCT-3′
(reverse primer); TRAILR4: 5′-GGAGACAGTGACCAC
CATCC-3′ (forward primer), 5′-CGCCGGAAAAGGACT
CTGT-3′ (reverse primer).
Flow cytometric analysis of cellular protein amounts
For measurements of cell surface receptor amounts, cells
were suspended in cold PBA (1 × 105 cells per sample, PBS
+ 0.05% (w/v) bovine serum albumin (BSA, Sigma-
Aldrich, Munich, Germany)+ 0.02% (w/v) NaN3 (Carl
Roth, Karlsruhe, Germany) in ddH20) containing primary
antibody (100 µl/sample, on ice). After 1 h incubation, cells
were washed with PBA and resuspended in PBA containing
secondary antibody (on ice, 1 h). Thereafter, cells were
washed with PBA and analyzed (MACSQuant Analyzer 10,
Miltenyi Biotec, Bergisch Gladbach, Germany). To com-
bine surface amount measurements with intracellular Ki67
measurements, cells stained for surface receptors were
washed with PBS and fixed with 4% paraformaldehyde (4%
PFA (v/v) in PBS, Merck, Darmstadt, Germany) for 10 min
at room temperature in the dark. After two times washing
with PBS, the pellet was resuspended in ice-cold PBS (10
μl) and 90 μl methanol (100%, −20 °C, Carl Roth, Karls-
ruhe, Germany) was added. Following 30 min of incubation
on ice, 50 μl PBA containing 5% (w/v) BSA (washing
solution) was added prior to centrifugation at 500 g for
5 min at room temperature. After two more washing steps,
cell pellets were suspended in 100 μl washing solution
containing primary antibody, and cells were incubated for 1
h at room temperature in the dark. After washing, cells were
incubated with 100 μl washing solution containing sec-
ondary antibody for 1 h at room temperature in the dark.
After a final wash, cells were resuspended in PBA, and
fluorescence was measured (MACSQuant Analyzer 10,
Miltenyi Biotec, Bergisch Gladbach, Germany). All flow
cytometric data were analyzed by FlowJo 7.6.1 (Tree Star
Inc.) or MACSQuantify (MACS Miltenyi Biotec, Bergisch
Gladbach, Germany).
Preparation and staining of cryosections
Spheroids were collected in a 1.5 ml reaction tube, washed
with PBS and fixed with 4% PFA for 10 min at room
temperature, followed by incubation with sucrose (30% (w/
v) in PBS; Carl Roth, Karlsruhe, Germany) for 48 h at 4 °C.
After removal of sucrose, 1 ml of Tissue Freezing Medium
(Tissue-Tek O.C.T Compound (TTEK); A. Hartenstein,
Würzburg, Germany) was added. Spheroids were stored at
−20 °C until usage. To prepare cryosections, samples were
mounted on precooled sample holders and cut into 10 μm
slices (CM30505 cryostat, Leica Biosystems, Wetzlar,
Germany). Sections were mounted on Polysine Microscope
Adhesion Slides (Thermo Fisher Scientific, Waltham, MA,
USA). After thawing, cryosections were fixed with 100%
methanol (Carl Roth, Karlsruhe, Germany) for 10 min at
−20 °C, washed with PBS and blocked with a BSA solution
(5% (w/v) in PBS) for 10 min at room temperature. After
washing again with PBS, sections were incubated with 100
μl peroxidase blocking reagent (Dako, Agilent Technolo-
gies, Santa Clara, CA, USA) for 5 min at room temperature
and, after washing, primary antibody (diluted in Antibody
Diluent (Dako, Agilent Technologies, Santa Clara, CA,
USA)) was added for 1 h at room temperature. Next, sec-
tions were washed with PBS and either incubated with 100
μl of a peroxidase labeled polymer, binding to rabbit or
mouse derived primary antibodies (Dako, Agilent Tech-
nologies, Santa Clara, CA, USA) for 30 min at room tem-
perature, or in case of the TRAILR1 antibody, which
derived from goat, samples were treated with 100 μl of a
bridging antibody (rabbit antigoat IgG, IgM, IgA, Gentaur,
Aachen, Germany) for 30 min at room temperature. Next,
sections were washed again with PBS, incubated with 100
μl of a substrate chromogen solution (chromogen 3, 3′-
Diaminobenzidine 1:50 in substrate buffer, Dako, Agilent
Technologies, Santa Clara, CA, USA) for 10 min and
washed under running water for 3 min. Cell nuclei were
stained with hematoxylin solution (Merck, Darmstadt,
Germany). Afterwards, cryosections were treated with
ethanol solutions (70%, 90%, 100%, each 3 min) and
incubated with the xylene substitute Neo-Clear (Merck,
Darmstadt, Germany) for 3 min. Stained cryosections were
mounted using Neo-Mount (Merck, Darmstadt, Germany).
Preparation and staining of paraffin sections
Spheroids were washed once with PBS and transferred into
an agarose bedding (4% (w/v) agarose in ddH2O). Spher-
oids were then stained with hematoxylin solution (Merck,
D. Stöhr et al.
Darmstadt, Germany) to identify spheroid locations.
Spheroids were then incubated with 4% PFA solution for
10 min at room temperature and, after removal of super-
natant, covered with 1% agarose. Agarose cores were
transferred into 4% PFA in embedding cassettes. Samples
were dehydrated and embedded in paraffin. In total, 3 μm
slices were cut with a rotary microtome (RM 2255 Mikro-
tom, Leica Biosystems, Wetzlar, Germany) and sections
were transferred to glass slides before they were incubated
at 56 °C overnight, prior to storage. Sections were depar-
affinized with Neo-Clear solution (Merck, Darmstadt, Ger-
many) for 30 min at room temperature and rehydrated with
decreasing concentrations of ethanol (100%, 96%, 70%)
and H2O (3 min each). Next, samples were incubated with
Dako target retrieval solution pH 6 (Dako, Agilent Tech-
nologies, Santa Clara, CA, USA) for 30 min inside a steam
cooker and afterwards washed two times for 3 min with 1 ×
TBST (Tris-buffered saline with 0.1% (v/v) Tween-20, Carl
Roth Karlsruhe, Germany). Treatment with peroxidase
blocking reagent (Dako, Agilent Technologies, Santa Clara,
CA, USA) and staining steps were conducted as
described above.
Immunostaining of cryosections
Sections were washed with PBS, followed by fixation for
10 min at room temperature with 4% PFA and two
washing steps with PBS for 5 min. After permeabilisation
with 0.1% (v/v) Triton X-100 (Carl Roth, Karlsruhe,
Germany) in PBS at room temperature for 10 min, sec-
tions were treated with blocking solution (5% (v/v) FCS
and 0.1% (v/v) Triton X-100 in PBS) at room temperature
for 30 min, and then incubated with the primary anti-
bodies for 1 h at room temperature. Sections were washed
twice and incubated with the Alexa 647-conjugated sec-
ondary antibodies for 1 h at room temperature. After two
washes, DNA was stained using DAPI (1 μg/ml in PBS,
10 min, room temperature). Following two washes in
PBS, coverslips were mounted on top of glass slides using
Fluoromount-G (Southern Biotechnology Associates,
Birmingham, AL, USA).
Analysis of sections
Cryosections were analyzed using a laser scanning micro-
scope (LSM 710, Carl Zeiss, Germany) and Zen 2010 black
edition (Carl Zeiss, Germany). Alternatively, stained
spheroids sections were imaged using a bright field slide
scanner (Leica SCN400, Leica Microsystems, Wetzlar,
Germany), and images were analyzed using Definiens Tis-
sue Studio 64 software (Definiens AG, Munich, Germany).
Photoshop Elements 10 software (Adobe Systems, San
José, CA, USA) was used to determine percentages of
stained cells and their intensities in spheroid layers.
Western blotting
2D-cultured cells and spheroids were washed with ice-cold
PBS before they were incubated on ice in RIPA buffer
(150 mM NaCl, 0.1% Triton X-100, 0.5% sodium deox-
ycholat, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris in
ddH2O, pH 8; all chemicals from Carl Roth, Karlsruhe,
Germany) for 5 min, sonicated (6 pulses, Bandelin Sono-
puls HD 200, BANDELIN electronic GmbH & Co. KG,
Berlin, Germany), and incubated for another 5 min on ice.
Cellular debris was removed by centrifugation at 20,000 g
for 20 min. Protein concentrations were quantified by
Bradford assay. Equal amounts of proteins were supple-
mented with 5 × Laemmli sample buffer (10% SDS, 312.5
mM Tris pH 6.8, 25% β-mercaptoethanol, 25% glycerin,
0.05% bromphenol blue, all chemicals were purchased from
Carl Roth, Karlsruhe, Germany) and heated to 95 °C for 5
min. Proteins were separated on Nu-Page 4–12% Bis-Tris
gels (Invitrogen, Carlsbad, CA, USA) and transferred to
nitrocellulose membranes using an iBlot 2 gel transfer
device (Invitrogen, Carlsbad, CA, USA). After 1 h blocking
with blocking reagent (Roche Diagnostics, Mannheim,
Germany) diluted in TBST (1%) the membranes were
incubated with primary antibodies (diluted in TBST with
0.5% blocking reagent) overnight. After washing with
TBST, membranes were incubated either with an HRP-
coupled secondary antibody (diluted in TBST with 0.5%
blocking reagent) or an IRDye-conjugated secondary anti-
body (diluted in TBST with 0.5% blocking reagent) for 1 h
at room temperature. Following three further washing steps,
proteins were detected by either directly measuring fluor-
escence with an infrared imager (LI-COR Odyssey, LI-
COR Biosciences, Lincoln, NE, USA) or incubating the
membrane with an HRP substrate (SuperSignal West Pico
ECL Substrate/SuperSignal West Dura Extended, Thermo
Scientific Pierce Protein Biology, Waltham, MA, USA;
Luminata Forte Western HRP Substrate, Merck Millipore,
Burlington, MA, USA) and detecting the signals with an
ECL imager (Amersham Imager 600, GE Healthcare,
Freiburg, Germany GmbH).
Calculation of the coefficient of drug interaction
(CDI)
CDIs were calculated according to Cao and Zhen [16].
CDI ¼ E ABð ÞE Að ÞE Bð Þ where E(A), E(B), and E(AB) are the ratios,
in percentage of surviving cells, following treatment with
drug A, B, and A+ B, respectively, in comparison to control
groups. CDIs < 1 indicate synergism.
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Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 (GraphPad Software, San Diego, CA, USA). Data are
shown as mean values plus and minus the standard
deviation (SD) or standard error of the mean (SEM) as
stated in the figure legends. Statistical significance of
differences between groups was verified using the
stated significance tests. Significance level were denoted
with asterisks: *p ≤ 0.5; **p ≤ 0.01; ***p ≤ 0.001.
D. Stöhr et al.
Means were calculated from independently performed
experiments.
Results
TRAIL-resistant cell layers protect TRAIL-sensitive
cells within cancer cell spheroids
We generated spheroids of HCT116 and NCI-H460 cells to
study TRAIL responsiveness in 3D culturing conditions.
Spheroids reached a diameter of 500–600 µm after 11 days
of cultivation and resembled the size and structure of
avascular micrometastases, consisting of an outer pro-
liferative cell layer surrounding largely quiescent cells
(Supplementary Fig. 1a, b). Compared with HCT116 cells
cultured in 2D, HCT116 spheroids were substantially more
resistant to TRAIL (Fig. 1a, f). Experiments with pan-
caspase inhibitor Q-VD-OPH (QVD) verified that spheroid
cells died by apoptosis (Fig. 1b). Interestingly, dissociating
the spheroids prior to treatment not only eliminated the
increased TRAIL resistance but surprisingly revealed that
sizeable subpopulations of cells with an increased
TRAIL sensitivity must exist within spheroids (Fig. 1c, f).
Similar findings were made in NCI-H460 cells (Fig. 1d–f).
Together, these data suggest that TRAIL-hypersensitive
cells are protected from cell death within intact spheroids,
likely due to TRAIL-resistant cells in outer layers of the
spheroids.
Next, we investigated if increased TRAIL resistance in
intact spheroids correlates with changed expression of
apoptosis regulators in 3D growth conditions. Notably,
transcript amounts for both TRAILR1 and R2 dropped
when comparing 2D- and 3D-cultured HCT116 and NCI-
H460 cells (Fig. 1g, h). Correspondingly, average cell sur-
face amounts of these receptors likewise decreased, with the
exception of TRAILR2 in HCT116 cells (Fig. 1i, j). His-
togram analyses identified that the entire populations of
HCT116 and NCI-H460 cells lose TRAILR1 expression
(Fig. 1k, l). HCT116 cells expressed only low amounts of
TRAILR2, with a substantial proportion of the population
overlapping with the negative control in both 2D and 3D
growth scenarios (Fig. 1k). In NCI-H460 cells, TRAILR2-
surface amounts dropped considerably, however, the right
shoulder of the distribution indicated that a subpopulation
of cells still retains TRAILR2 surface expression in
amounts at least as high as in the 2D growth scenario
(Fig. 1l). Other tested apoptosis regulators, among them
DISC components such as FADD and procaspase-8 as well
as procaspases-9 and -3 and their inhibitor XIAP, did not
change in their expression between 2D and 3D growth
conditions. In contrast, cFlip isoforms were downregulated
in spheroids. However, the downregulation of these anti-
apoptotic proteins cannot be accountable for the overall
increased TRAIL resistance of spheroids (Supplementary
Fig. 2).
Together, these data suggest that a population of TRAIL-
hypersensitive cells is protected from cell death within
intact spheroids, likely due to TRAIL-resistant cells in outer
layers of the spheroids, and that differences in the expres-
sion of TRAILR1 and TRAILR2 might account for the
observed changes in TRAIL susceptibility.
Spatial patterns of TRAILR1/R2 expression correlate
with TRAIL responsiveness in tumor cell spheroids
If changes in TRAILR1 and TRAILR2 surface amounts
alter TRAIL responsiveness in 3D growth conditions, it
would be expected that their expression patterns in spheroid
cross-sections correlate with high TRAIL responsiveness in
outer and inner but not in intermediate cell layers. We
therefore immunohistochemically stained medial sections of
HCT116 and NCI-H460 spheroids for TRAILR1 and
TRAILR2, and color coded the spheroid sections according
to absent, low, medium, and high receptor expression
(Fig. 2a). Quantification of receptor amounts in spheroid
layers, from the inside to the spheroid surface, provided
evidence matching our expectations. TRAILR1 expression
was highest in the outermost spheroid layers
(HCT116 spheroids: layer 6; NCI-H460 spheroids: layers 5
and 6) and absent or low in the innermost layers (Fig. 2b).
In HCT116 spheroids, 80% of all cells in the outermost
Fig. 1 TRAIL-resistant cell layers protect TRAIL-sensitive cells
within tumor cell spheroids. a, d Cell viability in HCT116 and NCI-
H460 cells, grown in 2D or as spheroids (day 11), following 6 h of
treatment with TRAIL. The loss of viability was measured flow
cytometrically by staining with Annexin V-EGFP. Data shown are
mean values ± SEM from three independent experiments. Insets serve
as illustrations. b Cell viability in response to TRAIL (3.55 nM),
measured as in (a), in the presence or absence of pan-caspase inhibitor
QVD-OPH (50 µM). Data show mean values ± SEM from three
independent experiments. c, e 2D-cultivated HCT116 and NCI-H460
cells were detached and HCT116 and NCI-H460 spheroids were dis-
sociated before treatment as in (a, d). Insets serve as illustrations. f The
table shows the EC50 values determined by nonlinear regressions from
(a, c, d, and e) (sigmoidal dose response). g, h Transcript amounts of
TRAILR1 and TRAILR2 (long and short isoforms) in 2D-cultivated
cells and cells grown as spheroids (day 11), as measured by qPCR.
Relative RNA amounts were calculated by the ΔΔCt method using
GAPDH for normalization. Data shown are mean values ± SEM from
three independent experiments. i–l Surface expression of TRAILR1
and TRAILR2. 2D-cultivated cells and cells from spheroids (day 11)
were analyzed by flow cytometry. Histograms are representative of at
least three independent experiments. Population medians were used to
calculate the differences in relative surface expression between 2D-
and 3D-cultivated cells. AU arbitrary units. Bar graphs show mean
values ± SD of at least three independent experiments. Asterisks
indicate statistical significance (*p ≤ 0.05; **p ≤ 0.01; ns not sig-
nificant; unpaired t-test).
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layer and 80–100% of all cells in the two innermost
spheroid layers displayed high TRAILR2 amounts
(Fig. 2b). In contrast, the percentage of cells with high
TRAILR2 expression in the intermediate layers was
substantially reduced. Qualitatively similar results were
obtained for NCI-H460 spheroids (Fig. 2b). The antibodies
used did not cross react between TRAILRs, ensuring spe-
cificity of the obtained signals (Supplementary Fig. 3a, b).
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From the pooled TRAILR expression data, we recon-
structed representative spheroids to more intuitively visua-
lize spatial TRAILR expression patterns (Fig. 2c). Besides
high expression of both TRAILRs in the outer spheroid
layers, high amounts of TRAILR2 were found in spheroid
centers, in particular in the vicinity of dead cores that begin
to form in older spheroids. We independently confirmed
these results by flow cytometry, co-staining cells for
TRAILRs and for Ki67 as a marker for proliferating cells in
outer spheroid cell layers (Fig. 2d). The expression of Ki67
and the abundance of TRAILR1 strongly correlated
(Fig. 2e), whereas surface TRAILR2 expression was the
highest in those cells displaying the strongest and the
weakest Ki67 signals, respectively (Fig. 2e). High expres-
sion of TRAILR1/R2 in the outermost layers also
correlated with caspase-3 processing being limited primarily
to these layers in spheroid cross-sections (Supplementary
Fig. 3c, d).
Together, these data reveal a cross-sectional pattern of
high TRAILR expression in surface layers, followed by low
expression or the absence of TRAIL receptors in inter-
mediate layers, and finally high TRAILR2 expression in the
innermost layers of tumor cell spheroids.
TRAILR2 expression is essential for TRAIL
hypersensitization within tumor cell spheroids
To study if TRAILR2 is required for TRAIL hypersensitiza-
tion within tumor cell spheroids, we targeted TNFRSF10B by
CRISPR/Cas9-mediated gene knockout. The resulting cells
lost TRAILR2 surface and overall TRAILR2 protein expres-
sion, without significantly affecting the amounts of TRAILR1
(Fig. 3a, b, Supplementary Fig. 4a). When grown as spheroids,
the surface expression of TRAILR1 in HCT116 TRAILR2 k/o
cells dropped like in parental HCT116 cells (Supplementary
Fig. 4b and Fig. 1k). The loss of TRAILR2 only moderately
protected HCT116 cells grown in 2D but strongly protected
these cells when grown as spheroids (Fig. 3c). While cells
from dissociated parental HCT116 spheroids were TRAIL-
hypersensitive, HCT116 TRAILR2 k/o cells remained sub-
stantially more resistant (Fig. 3d, e). Similar findings were
made in NCI-H460 T2 k/o spheroids (Fig. 3f, g, h). To verify
that solely TRAILR2 but not TRAILR1 is accountable for the
TRAIL-hypersensitivity of cells close to the spheroid center,
we also targeted TNFRSF10A in HCT116 and NCI-H460 cells
(Supplementary Fig. 4a). In contrast to the knockout of
TRAILR2 and as expected, knockout of TRAILR1 did not
further increase the TRAIL resistance of intact spheroids
(Supplementary Fig. 5a, c) since TRAILR1 expression is
already largely lost in inner layers of spheroids grown from the
parental cells (Fig. 2a–c). Consequently, knockout of
TRAILR1 failed to abrogate TRAIL-hypersensitive cell
populations in dissociated spheroids (Supplementary Fig. 5b,
d, e, f). These results therefore demonstrate that the presence
of TRAILR2 but not TRAILR1 is essential for populations of
TRAIL-hypersensitive cells to develop within multicellular
spheroids.
Oxygen and nutrient deprivation result in
accumulation of TRAILR2
With growing spheroid sizes, microenvironmental stress
increases, in particular within the center of avascular cell
masses, typically arising from a lack of oxygen and nutri-
ents [15]. Therefore, we next sought to identify which stress
factors are linked to the accumulation of TRAILR2 in the
center of spheroids.
In older spheroids, excessive stress results in the for-
mation of dead cores. We therefore first tested if TRAILR
deregulation can already be observed prior to the formation
of dead spheroid centers. We noted that TRAILR2 dereg-
ulation begins to manifest on day 7, several days before
necrotic cores develop (Supplementary Fig. 6), and there-
fore cannot be a consequence of a microenvironment altered
by dying cells.
Comparing 2D and 3D growth conditions, we found
that cells grown as spheroids induce hypoxia-inducible
factor-1α (Hif-1α), a canonical marker for oxygen
deprivation (Fig. 4a). Likewise, cells obtained from
spheroids presented with altered amounts or balances of
lipidated and unlipidated microtubule-associated proteins
1A/1B light chain 3B (LC3B), indicative of nutrient
deprivation (Fig. 4b). Stress appeared to manifest pri-
marily within the center regions of spheroids and to
increase over time, as shown for Hif-1α accumulation and
localization (Fig. 4c, d). To study if TRAILR2 expression
is a consequence of these stress factors, we next repli-
cated hypoxia and nutrient deprivation in conventional
cell culturing conditions. Hypoxia indeed resulted in a
Fig. 2 Spatial patterns of TRAILR1/R2 expression correlate with
TRAIL responsiveness in tumor cell spheroids. a Spheroid slices
(day 11) were immunohistochemically stained for TRAILR1 or
TRAILR2 and counterstained with hematoxylin. TRAILR staining
intensity was color coded (absent (blue), low (yellow), medium
(orange), and high (red)). Scale bars= 100 μm. b TRAILR expression
in spheroid layers. Percentage of cells with no, low, medium, and high
TRAILR expression are shown are mean values ± SEM from n=
3 spheroids. c Representative spheroid cross-sections were recon-
structed based on mean spheroid metrics (spheroid diameter, cell
number, TRAILR expression amounts) and color coded as in (a) and
(b). d Spheroids slices (day 11) were fixed and stained for Ki67.
Nuclei were stained with DAPI. Images are representative of three
independent experiments. Scale bars= 100 µm. e Cells isolated from
spheroids (day 11) were flow cytometrically analyzed for surface
TRAILR amounts and, following permeabilization, Ki67. Scatter plots
are representative of three independent experiments. R2 were obtained
for linear regression. Table shows Spearman’s rank correlation coef-
ficient (ρ) rho and associated probability values.
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pronounced accumulation of total and surface exposed
TRAILR2 in both NCI-H460 and HCT116 cells (Fig. 4e, f).
Glucose starvation likewise induced substantial accumulation
of TRAILR2 in both cell lines, while serum starvation caused
strong accumulation of TRAILR2 only in NCI-H460 cells
(Fig. 4g, h).
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From these data we conclude that hypoxia and nutrient
deprivation, primary stress factors within 3D growth
environments, are sufficient to cause TRAILR2 accumula-
tion similar to what is observed within the centers of
spheroids.
COX-II inhibitor celecoxib enhances TRAILR2
expression and synergizes with TRAIL treatment in
eliminating cancer cell spheroids
We next studied if the expression of TRAILR2, which is
lost or reduced in intermediate spheroid cell layers, can be
restored in order to enhance TRAIL responsiveness in 3D
growth conditions. Celecoxib is an FDA-approved non-
steroidal anti-inflammatory drug that can enhance
TRAILR2 expression in conventionally cultured colon and
prostate cancer cells, presumably through inducing ER
stress and the expression of CHOP, a major ER stress-
induced transcription factor known to promote TRAILR2
expression [17, 18]. Indeed, celecoxib induced CHOP in
HCT116 and NCI-H460 cells (Supplementary Fig. 7a) and
resulted in pronounced accumulation of TRAILR2 but not
TRAILR1 in cancer cell spheroids (Fig. 5a). The expression
of DISC components FADD, cFlip or procaspase-8 was not
affected by celecoxib treatment (Supplementary Fig. 7b).
Analyzing spheroid cross-sections revealed that TRAILR2
expression in the presence of celecoxib was no longer
restricted to the outer and innermost spheroid layers but was
also found in high amounts in intermediate cell layers
(Fig. 5b, c). The upregulation of TRAILR2 indeed sub-
stantially sensitized both HCT116 and NCI-H460 spheroids
to TRAIL treatment (Fig. 5c), with clear indications for
pronounced response synergies for this combination treat-
ment in both cell line models (Fig. 5d). On the contrary,
stimulating 2D-cultured HCT116 TRAILR2 k/o cells and
HCT116 TRAILR2 k/o spheroids with celecoxib failed to
sensitize the cells to TRAIL, indicating that after the com-
bination treatment cells died due to an increase in TRAILR2
expression (Fig. 5e, f). Celecoxib treatment therefore seems
sufficient to increase TRAILR2 expression in intermediate,
otherwise TRAIL-resistant spheroid layers, offering a tan-
gible opportunity to improve responsiveness to TRAIL-
based therapeutics.
Discussion
Here, we identified that pronounced, spatially coordinated
TRAIL response heterogeneities manifest within cancer cell
spheroids, leading to the development of TRAIL-resistant
cell layers that enclose TRAIL-hypersensitive cells.
Reduced TRAIL responsiveness arises from the loss of
TRAILR1 and R2 expression. Importantly, microenviron-
mental stress, such as nutrient and oxygen deprivation,
together with pharmacologically induced ER stress, are
sufficient to restore TRAILR2 expression and treatment
responsiveness.
While TRAILRs are preferentially expressed in cancer
cells and are a prerequisite for TRAIL responsiveness [19–
22], surprisingly little is known about the heterogeneity of
TRAILR expression within individual tumors. Corre-
sponding to our findings in the outer proliferative layers of
spheroids, the invasive fronts of colon tumors express high
amounts of TRAILR2 [23]. Indeed, proliferation and inva-
sion of various cancers might at least in part depend on
autonomous TRAILR signaling. For example, it was
recently shown that TRAIL/TRAILR2 signaling increases
migration and invasion via a Rac1/PI3K signaling axis in
KRAS mutated nonsmall-cell lung cancer and pancreatic
ductal adenocarcinomas [24]. Additional “non-canonical”
signaling upon activation of TRAILRs likewise promotes
cell proliferation, including the activation of the NF-κB
pathway as well as JUN kinase and MAP kinase signaling
[25–29]. In addition to its cell surface receptor function,
nuclear TRAILR2 suppresses the maturation of miRNA let-
7 and thereby promotes the proliferation of pancreatic
cancer cells [30]. While TRAILR expression obviously is
essential for apoptosis induction by TRAILR agonist-based
therapeutics, tumor autonomous nonapoptotic signaling
through TRAILRs is associated with poor patient outcome
in current clinical settings. For example, TRAILR2
expression is associated with poor prognosis in pancreatic
cancer and KRAS mutated colon cancer [24]. Similarly,
high amounts of TRAIL prognosticate poorer outcome of
patients with stage II and III colorectal cancer [31]. We
showed that cells close to dead cores of cancer cell spher-
oids are hypersensitive to TRAIL, and that this hypersen-
sitivity requires the presence of TRAILR2. These cells
appear to experience substantial microenvironmental stress,
Fig. 3 TRAILR2 expression is essential for TRAIL hypersensiti-
zation within tumor cell spheroids. a, b TRAILR surface expression.
HCT116/NCI-H460 wildtype (WT) and HCT116/NCI-H460
TRAILR2 knockout (T2 k/o) cells were analyzed by flow
cytometry. Histograms are representative of two independent experi-
ments. c, d, f, g HCT116/NCI-H460 cells or HCT116/NCI-H460
TRAILR2 knockout (T2 k/o), grown in 2D or as spheroids (day 11)
were stimulated with TRAIL for 6 h. In (d, g), cells were detached, or
spheroids were dissociated prior to treatment. Loss of viability was
measured flow cytometrically by Annexin V-EGFP staining. Data
shown are mean values ± SEM from three independent experiments,
with exception of HCT116 T2 k/o cells in (d), where bars indicate
range (n= 2). The experiment shown in (f) was performed side by side
with the experiment shown in supplementary Fig. 5c, thus the curves
derived from WT cells (2D and 3D) are identical. The same is true for
the data shown in (g) and in supplementary Fig. 5d. Insets serve as
illustrations. e, h EC50 values obtained from nonlinear regressions
(sigmoidal dose response). Minus sign indicates cases in which the
EC50 could not be calculated.
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due to oxygen and nutrient deprivation. The absence of
glucose enhances TRAILR2 transcription and protein
accumulation in HeLa cells as a consequence of ER stress
[32], as does treatment with 2-deoxy-D-glucose, an anti-
metabolic glucose derivative [33]. Hypoxia-induced
TRAILR2 expression has likewise been described, but
this response seems to differ notably between cell lines [34].
Regarding the reasons underlying the accumulation of
TRAILR2 in cells close to spheroid cores it is therefore
conceivable that a prolonged and extensive oxygen and
nutrient deprivation results in robust induction of ER stress
and in the activation of the unfolded protein response.
Interestingly, besides elevated cell surface amounts of
TRAILR2, this TRAIL receptor can also accumulate
Fig. 4 Oxygen and nutrient deprivation result in accumulation of
TRAILR2. a, b Cell lysates of 2D-cultivated cells or cells grown as
spheroids (day 11) were analyzed by western blotting. Blots are
representative of three independent experiments. c Paraffin-embedded
spheroid slices (day 11) were immunohistochemically stained for Hif-
1α and counterstained with hematoxylin. Cells were color coded as
positive (yellow) or negative (blue). Pictures are representative of three
independent experiments. Scale bars= 200 μm. d Percentages of cells
positive or negative for Hif-1α expression are shown as mean values ±
SD of 4–16 spheroids from 3 independent experiments. Asterisks
indicate statistical significance (***p ≤ 0.001; unpaired t-test).
e Lysates from cells cultivated at 1% O2 were analyzed by western
blotting. Blots shown are representative of three independently per-
formed experiments. f TRAILR2 surface expression measured by flow
cytometry. Medians of the cell populations were used to calculate
surface expression relative to cells cultivated at control conditions.
Data are mean values ± SD of at least three independent experiments.
g Lysates from cells cultivated at starvation conditions were analyzed
by western blotting. Blots shown are representative of three indepen-
dently performed experiments. h TRAILR2 surface expression mea-
sured by flow cytometry. Medians of the cell populations were used to
calculate surface expression relative to cells cultivated at control
conditions. Data are mean values ± SD of at least three independent
experiments.
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intracellularly in response to ER stress and thereby con-
tribute to ligand independent but caspase-8-dependent
apoptosis [32, 35–37] Correspondingly, directly inducing
persistent ER stress by thapsigargin promotes TRAILR2
accumulation and apoptotic cell death [36]. Even though
cells deprived of oxygen and nutrient within the centers of
spheroids or micrometastases ultimately will die, it could be
speculated that elevated TRAILR2 expression close to
spheroid cores contributes to this being an ordered cell
death process. The presence or absence of TRAILR2 and
apoptosis as a route toward a subsequently phenotypically
necrotic core might substantially affect microenvironmental
inflammatory signals and cytokine profiles, and by exten-
sion the ER stress-dependent immunogenicity of cell death
within spheroids [38–40]. Interestingly, cells at the interface
of proliferative and quiescent spheroid layers loose both
TRAILR1 and R2 expression and thereby reduce the overall
TRAIL responsiveness of intact spheroids. TRAILR defi-
cient cells reside in regions in which microenvironmental
stress would be considered moderate. Nevertheless, this
Fig. 5 COX-II inhibitor celecoxib enhances TRAILR2 expression
and synergizes with TRAIL treatment in eliminating cancer cell
spheroids. a Cells grown in 2D or as spheroids (day 11) were treated
with 50 μM celecoxib for 72 h. TRAILR expression was determined
by flow cytometry. Data are shown as mean values ± SEM from at
least three independent experiments. b HCT116 spheroids (day 11)
were stimulated with 50 μM celecoxib for 72 h. Paraffin-embedded
slices were immunohistochemically stained for TRAILR2 and coun-
terstained with hematoxylin. Cells were color coded according to
TRAILR2 expression amounts (absent (blue), low (yellow), medium
(orange) and high (red)). Images are representative of two independent
experiments. Scale bars= 100 μm. c, d Spheroids of HCT116 and
NCI-H460 cells (day 11) were stimulated with 50 µM celecoxib for 72
h, with TRAIL added after 48 h. The loss of viability was determined
flow cytometrically by Annexin V-EGFP staining. Data show mean
values ± SEM of three independent experiments. Asterisks indicate
statistical significance (*p ≤ 0.05, ***p ≤ 0.001, ns not significant;
Two-way ANOVA with Bonferroni correction). Data from (c) served
to calculate the coefficient of drug interaction (CDI), with values < 0.7
indicating strong synergism (d). e, f Cells grown in 2D or as spheroids
(day 11) were stimualted with 50 µM celecoxib for 72 h, with 0.6 nM
TRAIL added after 48 h. Viability loss was determined by Annexin V-
EGFP staining and flow cytometry. Data are mean values ± SEM from
three independent experiments.
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seems sufficient for TRAILR deregulation, as also sup-
ported by studies investigating scenarios of mild, nonlethal
stress. For example, limiting oxygen supply drives PI3K
signaling [41], which in turn can support hedgehog sig-
naling and expression of GLI3, a repressor of TRAILR1
transcription [42–44]. Furthermore, the mRNA binding
protein HuR was suggested to inhibit TRAILR2 translation
under such conditions [45]. Since the ER folding and gly-
cosylation capacity depends on nutrient supply, it is note-
worthy that under moderate ER stress TRAILR2 mRNA is
degraded via IRE1α signaling [36]. Overall, it is therefore
conceivable that at conditions of mild deprivation of
nutrients or oxygen, not only proliferation slows down but
also TRAILR expression is downregulated, thereby
increasing apoptosis resistance. The mechanistic basis for
this, however, seems highly complex.
We succeeded in counteracting the development of
TRAIL-resistant cell layers by intensifying microenviron-
mental stress by ER stress inducer celecoxib. Celecoxib is
an FDA-approved, nonsteroidal anti-inflammatory drug,
targeting COX-II but also evoking COX-II independent ER
stress [46, 47]. Both COX-II inhibition as well as COX-II
independent ER stress potently induce TRAILR2 expres-
sion [17, 18, 48–50]. However, TRAIL sensitization by
celecoxib was never studied in 3D growth scenarios. We
here demonstrate that treatment with celecoxib results in
enforced TRAILR2 expression in all spheroid layers,
accompanied by increased TRAIL sensitivity. Celecoxib
could therefore become an attractive co-treatment option in
future TRAIL-based therapies for solid tumors. Besides
TRAIL sensitization, antagonizing COX-II-linked cell pro-
liferation, tumor vascularization, and metastasis might
provide additional benefits [51–57].
Overall, our study provides novel and detailed insight
into how TRAIL response heterogeneities manifest within
well-defined multicellular environments, and how cells
within these environments can be manipulated to minimize
or eliminate barriers of TRAIL resistance.
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